Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. [electronic resource]
Producer: 20090901Description: 3547-53 p. digitalISSN:- 1791-7530
- Androgens -- physiology
- Base Sequence
- Cell Line, Tumor
- Cholecalciferol -- analogs & derivatives
- DNA Primers
- Humans
- Male
- Neoplasms, Hormone-Dependent -- drug therapy
- Polymerase Chain Reaction
- Prostatic Neoplasms -- drug therapy
- RNA, Messenger -- genetics
- Steroid Hydroxylases -- genetics
- Vitamin D3 24-Hydroxylase
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.